A 15-minute delayed phase when performing extra-cellular contrast agent enhanced MR imaging may improve diagnosis of hepatocarcinoma.
Adding a 15-minute delayed phase in extracellular contrast agent (ECA)-enhanced MR imaging may improve the diagnostic performance for hepatocellular carcinoma (HCC) in patients with chronic liver disease, according to a study published in the journal European Radiology.
Researchers from Korea sought to determine the value of a 15-minute delayed phase in ECA-enhanced MR imaging for evaluation of HCC in patients with chronic liver disease.
The researchers assessed the findings of 103 patients with chronic liver disease who underwent ECA-enhanced MRI; 133 lesions consisting of 107 HCCs, 23 benign lesions and three non-HCC malignancies were identified with pathological or clinical diagnosis. MRI images were reviewed by two abdominal radiologists independently using the European Association for the Study of the Liver (EASL) and Liver Imaging Reporting and Data System (LI-RADS) criteria. Imaging features observed in the 15-minute delayed phase were recorded.
The results showed that three or four additional HCCs were diagnosed among the 107 HCCs, according to the EASL criteria by adding the 15-minute delayed phase, increasing sensitivity:
• Reviewer 1, from 69.2–72 percent
• Reviewer 2, from 75.7–79.4 percent
Reviewers 1 and 2 upgraded one and four HCCs from LR-4 to LR-5 based on the LI-RADS, respectively. No additional findings were observed among 23 benign lesions.
The researchers concluded the inclusion of the 15-minute delayed phase in ECA-enhanced MRI may improve the diagnostic performance for HCC in patients with chronic liver disease.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.
Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
November 14th 2023Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.